echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > "730 Heights" of generic drug patents

    "730 Heights" of generic drug patents

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Author|totoro

    After the official implementation of the patent link in China, the first statement of the patent information registration platform came from the statement of Tide Pharmaceuticals on piperacillil.
    It made three types of declarations for the three patents registered for the original research drug, that is, waited for these patents to expire.
    Listed (3 patents all expire in 2023)
    .


    Tide Pharmaceuticals is not the first generic drug to be applied for registration of piperacillin in China.


    Generic drugs of pibacillil in the United States

    Generic drugs of pibacillil in the United States

    Five patents of piperacillil have been registered in the FDA Orange Book
    .


    In other words, generic drugs need to declare 5 patents in the United States


    At present, 5 generic drugs in the United States have obtained Tentative Approval after mid-2020 and have not yet been marketed
    .


    Qilu Pharmaceutical's products are one of them


    So why did Qilu Pharmaceutical choose 4 types of declarations for patent challenge in the United States, but choose not to go on the market temporarily in China, and Tide Pharmaceuticals also choose 3 types of declarations?

    Potential threat of 730 crystal patent

    Potential threat of 730 crystal patent

    Judging from the current US litigation situation, almost all companies have made “invalid or non-infringement” statements on the three patents 612,489,168, indicating that these three patents do not pose too much threat
    .


    However, the 730 crystal patent, which was only registered in 2020, has brought certain obstacles to the listing of generic drugs


    Although Qilu Pharmaceutical submitted the ANDA earlier and did not need to declare the 730 patent, Pfizer still moved the 730 patent out of its lawsuit in 2021.
    Pfizer believes that "Qilu submitted a listing application with full knowledge of the 730 patent, and it was unreasonable.
    It is believed that it will be liable for the infringement of the 730 patent
    .


    ” In addition, after registering the 730 patent, Pfizer successively accused Natco Pharma, Mylan, AUROBINDO PHARMA LTD, DR.


    Therefore, although Qilu's generic drug made 4 types of declarations on 3 patents, on the one hand, it failed to go on the market due to the pending litigation and the 30-month waiting period; on the other hand, even the threat of 3 patents was resolved.
    , Still need to face the accusation of the 730 patent
    .

    In the database of the State Intellectual Property Office, a patent of the same family of 730 in China was retrieved, which was published before the generic drug application
    .


    Although China's patent information registration platform cannot register crystal patents, after generic drugs are marketed, the original drugs can still be sued for this patent


    From the current point of view, Pfizer is full of confidence in the role of the 730 patent
    .


    So, what is the value of the 730 patent? The claims involved in this patent are three claims defined by X-ray powder diffraction peak positions and particle size distribution values


    Enlightenment of generic drug patent link

    Enlightenment of generic drug patent link

    (1) Differences in the courts of first instance between China and the United States

    The courts of first instance jurisdiction for ANDA litigation in the United States are district courts, which may cause problems such as inconsistent trial standards and low efficiency
    .


    In October 2019, Pfizer simultaneously filed an ANDA lawsuit against piperacillil against 13 companies, 12 of which chose the Delaware Court, and one lawsuit against Mylan Enterprises chose the West Virginia District Court


    (2) Clarify the supplementary registration rules of the patent information platform

    U.
    S.
    Orange Book patents can be supplemented for registration
    .
    Pfizer registered 730 patents at the end of 2020, 5 years after the first patent registration.
    This is a big blow to companies that filed an ANDA application in early 2019 and are about to "surpass" the 30-month waiting period
    .
    China's patent information registration platform has not clarified whether it can supplement the registration of patents (only it can be clearly modified)
    .
    The supplementary registration of patents after the launch of the original research drug brings certain uncertainty to the generic drugs, and the later the patent registration may weaken the correspondence with the original research drug
    .
    It is hoped that China will further clarify the rules for the supplementary registration of patents after the launch of original research drugs, and give generic drug companies clear expectations for the market
    .

    (3) The significance of crystal patents

    It is possible to register crystal form patents in the Orange Book of the United States, but China's patent information registration platform is currently unable to register crystal form patents
    .
    Whether to register a crystal-type patent is one of the focuses of disputes in the "Implementation Measures for the Early Resolution Mechanism for Patent Disputes (Draft for Comment)" jointly issued by the National Medical Products Administration and the State Intellectual Property Office in September 2020.
    Some people believe that, Crystal type patents are important material patents.
    Failure to register them in the patent information registration platform will not be conducive to the early resolution of disputes
    .
    Although the common opinion is that once the crystal patent enters the invalidation process, the possibility of maintaining its validity is extremely low (in other words, the inefficiency reaches more than 90%), this may also be one of the reasons why the patent information registration platform temporarily does not register the crystal patent.
    ; However, Xu Bo and others searched the patent reexamination and invalidation examination databases of the State Intellectual Property Office from February 14, 2020 to April 30, 2021, respectively, using the international classification numbers C07C, C07D, C07K, C12N, and A61K
    .
    Among the 65 decisions, the total invalidity rate for drug patents was 37%, the partial invalidity rate was 31%, and the maintenance effective rate was 32%.
    Among them, 15 decisions were made for salt and crystal patents.
    Ranked third in China, second only to compound patents and formulation patents, but its maintenance efficiency is the highest among all patent types (46.
    7%)
    .
    The data of Xu Bo et al.
    show that crystal form patents have become an important "defensive" patent besides the patents of the original drug compounds
    .

    Therefore, for innovative drug companies, it is of great significance to pay attention to the early layout of crystal forms of patents
    .
    Although crystal form patents cannot be included in the registration platform for the time being, use patents and composition patents that can be rewritten into crystal forms are included in the registration platform
    .
    For generic drug companies, it is necessary to circumvent the potential crystal patents of the original research drug or prepare for invalidation challenges in the early stage of research and development
    .

    Reference source:

    ① FDA

    ② USPTO PATENT FULL-TEXT AND IMAGE DATABASE

    ③ ORANGE BOOK

    ④ WestLaw database

    ③ State Intellectual Property Office Database

    ④ CDE patent information registration platform

    ⑤ News of Pfizer suing two Indian companies: https://gabionline.
    net/generics/general/Pfizer-sues-Aurobindo-and-Dr-Reddy-s-over-Ibrance-palbociclib-generics

    ⑥ News about Pfizer suing Qilu:

    https://lawstreetmedia.
    com/health/pfizer-sues-to-block-generic-version-of-breast-cancer-drugs/

    ⑦ News about Pfizer suing Natco Pharma

    https://lawstreetmedia.
    com/health/pharmaceuticals/pfizer-alleges-patent-infringement-against-natco-pharma/

    ⑧[Empirical Research] Data Analysis of China's Drug Patent Invalidation after the "Sino-US Economic and Trade Agreement"

    https://mp.
    weixin.
    qq.
    com/s?src=11×tamp=1629377317&ver=3262&signature=6MW3H16JgWIiB51HMG*xU9MWQGa77Pm3JLuC0b0Thd4hL5F*aUa4*16gnRXQwHLz4qrvm4XiSikfGhe33fUd

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.